Vizsgálati helyszín
Brain Research Center Zwolle B.V.
Zwolle, 8025 AZ, HollandiaMég nincs intézményhez kötve
- 11futó vizsgálat
- 14lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 25 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis13 vizsgálat
- 3. fázis9 vizsgálat
- 1. fázis3 vizsgálat
- Állapot
- Lezárult14 vizsgálat
- Toboroz6 vizsgálat
- Fut, nem toboroz3 vizsgálat
- Még nem toboroz2 vizsgálat
- Fő szponzor
- Hoffmann-La Roche3 vizsgálat
- Bristol-Myers Squibb2 vizsgálat
- F. Hoffmann-La Roche AG2 vizsgálat
- Glaxosmithkline Research & Development Limited2 vizsgálat
- Merck Sharp & Dohme LLC2 vizsgálat
- és még 14
Futó vizsgálatok
Toboroz
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
NCT07781644· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
NCT07770841· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
NCT07328451· 1. fázis· Denali Therapeutics Inc.· Forrás
Fut, nem toboroz
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· 3. fázis· AstraZeneca· Forrás
Toboroz
A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.
2024-511110-21-00· 1. fázis· F. Hoffmann-La Roche AG· Forrás
Fut, nem toboroz
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526· 3. fázis· AriBio Co., Ltd.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease
2024-516966-12-00· 2. fázis· Novartis Pharma AG· Forrás
Lezárult
GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.
2025-521107-42-00· 2. fázis· Glaxosmithkline Research & Development Limited· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia
2024-515539-31-00· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE
NCT06079190· 2. fázis· Glaxosmithkline Research & Development Limited· Forrás
Lezárult
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
NCT06182085· 2. fázis· PRInnovation GmbH· Forrás
Lezárult
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)
2022-503148-41-00· 2. fázis· Prinnovation GmbH· Forrás
Lezárult
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
2023-504373-20-00· 2. fázis· Eip Pharma Inc.· Forrás
Lezárult
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
NCT05189210· 2. fázis· GemVax & Kael· Forrás
Lezárult
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s Disease
2023-504412-14-00· 1. fázis· F. Hoffmann-La Roche AG· Forrás
Lezárult
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
NCT05348785· 2. fázis· Biogen· Forrás
Lezárult
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease
2022-501188-42-00· 2. fázis· Janssen - Cilag International· Forrás
Lezárult
A study to assess how ALZ-801 affects laboratory tests and symptoms of Alzheimer's disease in patients who have a specific genotype (APOE4).
2024-515858-25-00· 2. fázis· Alzheon Inc.· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· 3. fázis· Eli Lilly and Company· Forrás
Hibát jelzek